Sun Pharma reports 12.6% sales growth for full year

30 May 2023
sunpharmabig

Leading Indian drugmaker Sun Pharmaceutical Industries (BSE: 524715) has reported financials for the full year ending March 31, 2023 (FY23).

Gross sales for the year came in at 432,789 million rupee ($5.24 billion), an increase of 12.6% over the previous year.

India formulation sales were 136,031 million rupees, up 6.6% over the previous year. US formulation sales were $ 1,684 million, up 10.3%, and global specialty sales were $871 million, up 29%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics